WINTON GROUP Ltd Sells 12,978 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• WINTON GROUP Ltd cut its Regeneron stake by 87.8% in the second quarter, selling 12,978 shares and retaining 1,800 shares valued at approximately $1.12 million.
• Other institutional investors generally increased their positions, and institutions collectively own 83.31% of REGN. Company insiders sold 4,146 shares worth about $3.43 million over the past 90 days.
• Regeneron exceeded quarterly earnings and revenue expectations, reporting EPS of $14.29 and revenue of $4.29 billion. Analysts maintain a “Moderate Buy” consensus with an average price target of $802.18.

WINTON GROUP Ltd trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 87.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,800 shares of the biopharmaceutical company's stock after selling 12,978 shares during the period. WINTON GROUP Ltd's holdings in Regeneron Pharmaceuticals were worth $1,122,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in REGN. Engineers Gate Manager LP increased its holdings in shares of Regeneron Pharmaceuticals by 4,309.4% during the 2nd quarter. Engineers Gate Manager LP now owns 15,918 shares of the biopharmaceutical company's stock worth $9,926,000 after acquiring an additional 15,557 shares during the last quarter. Cidel Asset Management Inc. boosted its position in Regeneron Pharmaceuticals by 7.8% during the second quarter. Cidel Asset Management Inc. now owns 775 shares of the biopharmaceutical company's stock worth $483,000 after purchasing an additional 56 shares during the period. Capital Analysts LLC increased its holdings in shares of Regeneron Pharmaceuticals by 25.0% in the second quarter. Capital Analysts LLC now owns 650 shares of the biopharmaceutical company's stock valued at $405,000 after purchasing an additional 130 shares during the last quarter. Pinnacle Wealth Management Advisory Group LLC increased its holdings in shares of Regeneron Pharmaceuticals by 12.3% in the second quarter. Pinnacle Wealth Management Advisory Group LLC now owns 2,713 shares of the biopharmaceutical company's stock valued at $1,692,000 after purchasing an additional 298 shares during the last quarter. Finally, NewEdge Advisors LLC raised its position in shares of Regeneron Pharmaceuticals by 56.5% in the second quarter. NewEdge Advisors LLC now owns 11,911 shares of the biopharmaceutical company's stock valued at $7,427,000 after purchasing an additional 4,301 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, EVP Marion Mccourt sold 1,131 shares of the stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total transaction of $969,708.09. Following the sale, the executive vice president directly owned 12,003 shares of the company's stock, valued at approximately $10,291,252.17. This represents a 8.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the firm's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the transaction, the director owned 603 shares in the company, valued at $512,550. The trade was a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 4,146 shares of company stock valued at $3,432,488. Company insiders own 6.97% of the company's stock.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of research reports. Canaccord Genuity Group cut their target price on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a "buy" rating for the company in a research note on Tuesday, May 19th. BMO Capital Markets lowered their price target on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an "outperform" rating on the stock in a report on Monday, May 18th. Piper Sandler cut their price objective on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating for the company in a research report on Thursday, July 9th. Wells Fargo & Company boosted their price objective on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an "equal weight" rating in a report on Friday, July 31st. Finally, Truist Financial upped their target price on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a "buy" rating in a research report on Friday, July 31st. Fourteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $802.18.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $781.49 on Monday. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $859.34. The company has a 50 day moving average of $754.93 and a 200-day moving average of $720.12. The company has a market cap of $80.46 billion, a price-to-earnings ratio of 19.32, a PEG ratio of 1.53 and a beta of 0.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same quarter in the prior year, the business posted $12.81 earnings per share. The firm's quarterly revenue was up 16.7% compared to the same quarter last year. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is presently 9.29%.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: RBC said Regeneron is increasingly likely to retain key patent protection for Eylea HD, a major commercial product. Preserving exclusivity could help protect revenue and earnings from biosimilar competition. Regeneron Pharmaceuticals More Likely to Retain Eylea HD Patent, RBC Says
• Positive Sentiment: HSBC raised its price target on REGN to $920 from $800 and maintained a Buy rating, implying substantial upside from the referenced share price. The move signals improved confidence in Regeneron’s outlook. HSBC Raises Regeneron Price Target
• Neutral Sentiment: A reported September short-interest figure of zero shares is not actionable because it is inconsistent with normal market data and produces a zero-day short-interest ratio.
• Negative Sentiment: Multiple law firms are promoting a securities class action against Regeneron, with a September 14 deadline for investors to seek lead-plaintiff status. The repeated notices add reputational and potential legal-cost risks, although they largely repeat the same lawsuit information rather than announce a new development. Regeneron Investor Deadline and Class Action Lawsuit
• Negative Sentiment: The lawsuit stems from the failure of a Phase 3 melanoma trial involving the Fianlimab-Libtayo therapy and allegations that Regeneron minimized statistical and protocol risks, including issues affecting progression-free-survival analysis. The trial failure reportedly erased about $11 billion in market value and raises concerns about the company’s pipeline and disclosure practices. Regeneron Clinical-Trial Risk Disclosure Lawsuit

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron's marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.